glp 1 and 2 agonist GLP-1 receptor agonists are increasingly used to treat type diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read GLP1 receptor agonist @nejm revisión

Description

Who Can Participate

S5 show that GLP-1RA were associated with lower risks as compared with placebo (16% lower risk), DPP-4 inhibitors (15% lower risk) and SGLT-2 inhibitors (10% lower risk), but the difference was statistically significant as compared with placebo only

If you have type 2 diabetes, GLP-1 medications address both weight and blood sugar, making them the clearly superior option

(2024b)

This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF